| Document |
Document Title |
|
WO/2004/113281A1 |
The present invention relates to tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. More precisely, the present invention relates to tricyclic derivativ...
|
|
WO/2004/110974A1 |
Compounds of formula (1): Wherein: Q represents an optionally substituted 5- or 6-membered aryl or heteroaryl ring; X represents 0, S, NR5 or CR6 R7; Y represents CHOH, CHSH, NOR8, CNR8 or CNOR8; Z represents a bond, CR10 R11, 0,S,S0,S02...
|
|
WO/2004/110418A2 |
Disclosed herein are carbonyl compounds of Formula (I), (II) or (III), and others as described herein. Also disclosed are methods of treating disease, such as cancer, neurological disorders, including polyglutamine-repeat disorders, anem...
|
|
WO/2004/110339A2 |
The invention provides novel methods for selective targeting of chemical compounds to cells undergoing a death process, in particular apoptosis, and to platelets undergoing activation during blood coagulation. The invention further provi...
|
|
WO/2004/111008A2 |
The invention relates to a compound of formula I or pharmaceutically acceptable salts thereof. The invention further relates to methods of use of this compound.
|
|
WO/2004/111086A2 |
The invention relates to peptide analogues or parent proteins comprising at least one type of aminoacyl aza-$g(b)3 residue and to the use thereof for pharmaceutical compositions or for diagnosis of pathologies involving said peptides or ...
|
|
WO/2004/108663A1 |
Fungicidal compounds of the general formula (1), wherein Ar is a group of the formula (A), (B1), (B2) or (C), or Ar is a 5- or 6-linked group of the formula (D1) or (D2); and R1, R2, R3, R4, R5, n, A1, A2, A3, A4, A5, Ka, Kb, L, M, V, W,...
|
|
WO/2004/108677A1 |
This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of fa...
|
|
WO/2004/108661A1 |
The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is dir...
|
|
WO/2004/103962A2 |
Aromachernical alkoxyalkyl sulfanyl compounds or a mixtures thereof having the formula: R1O-C6H5OH-SR wherein: R is a straight or branched chain, saturated or unsaturated hydrocarbyl group; preferably, alkyl or alkenyl, having 1-8 carbon...
|
|
WO/2004/103309A2 |
The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of dise...
|
|
WO/2004/103956A1 |
The invention relates to a method for the production of dithiodiglycol, wherein mercaptoethanol is reacted with oxygen in the presence of ammonia and/or amines using manganese salts or copper salts containing oxygen or gas mixtures conta...
|
|
WO/2004/103949A1 |
A (meth)acrylic ester compound represented by the general formula (1): (wherein R11 represents a divalent aromatic group; R12 represents hydrogen or methyl; R13 represents aryl; R14 represents hydrogen or methyl; and X11 represents oxyge...
|
|
WO/2004/101504A1 |
The invention relates to a stereoselective method of preparing $g(g)-amino vinyl sulphones. The inventive method comprises: the reaction of the corresponding N-protected (1-aminoalkyl) epoxide with a thiol, or an alkaline metal salt ther...
|
|
WO/2004/101506A1 |
This invention relates to compounds of formula (I) which are glyoxalase I inhibitors, pharmaceutical salts or compositions comprising such compounds, and the use of such compositions and compounds to treat various conditions alleviated b...
|
|
WO/2004/098516A2 |
The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, artherosclerosis and asthma.
|
|
WO/2004/099150A2 |
This invention provides compounds of formula (I) or a pharmaceutically acceptable salt thereof that are useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardia...
|
|
WO/2004/099171A2 |
Disclosed are compounds and pharmaceutically acceptable salts of formula (I): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include...
|
|
WO/2004/099129A2 |
Optically active 3-amino-butene and 1,2-dihydroxy-3-amino-butane intermediate compounds, useful in the synthesis of HIV-protease inhibitors and methods of preparing these intermediate compounds are disclosed (Formula I).
|
|
WO/2004/096761A1 |
The present invention relates to compounds of formula I wherein the substituents are as defined below. The compounds of formula I are useful for the treatment of diseases such as schizophrenia, including both the positive and the negativ...
|
|
WO/2004/094362A1 |
A compound of the following formula (1), its pharmaceutically acceptable salt or an optically active substance thereof. (in the formula, the symbols are as defined in the description). In particular, a compound having calcium sensitive r...
|
|
WO/2004/094650A2 |
The present invention is directed to labeled compounds, for example, isotopically enriched mustard gas metabolites including: [1,1',2,2'-13C4]ethane, 1,1'-sulfonylbis[2-(methylthio); [1,1',2,2'-13C4]ethane, 1-[[2-(methylsulfinyl)ethyl]su...
|
|
WO/2004/093800A2 |
Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed.
|
|
WO/2004/091604A1 |
This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods...
|
|
WO/2004/092119A2 |
The invention relates to an improved method for the production, purification and crystallisation of $g(a)-methylated cysteine or serine derivatives by an acid hydrolysis of corresponding thiazolidine or oxazolidine esters, with the conti...
|
|
WO/2004/091724A1 |
The present invention provides pharmaceutical compositions useful in treating hepatitis C infection. The present invention also provides methods of treating hepatitis C infection by administering to a mammal the pharmaceutical compositio...
|
|
WO/2004/092184A1 |
The aim of the invention is to propose substances, which after introduction into the body are mechanically stable vis-à-vis the chelate and are absorbed by the myocardium, and a method for producing said substances. Technetium-labelled ...
|
|
WO/2004/089876A1 |
Compounds of formula (I) or pharmaceutically acceptable derivatives thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.
|
|
WO/2004/090152A1 |
A process for producing a 2-alkylcysteinamide represented by the general formula (1) or a salt thereof, which comprises hydrolyzing a 4-alkylthiazolidine-4-carboxamide represented by the general formula (2) or a salt thereof. (In the gen...
|
|
WO/2004/089863A1 |
The invention relates to a process for the production of 2-hydroxy-4-methylthiobutyric acid ammonium salt from 2-hydroxy-4-methylthiobutyronitrile, and to the use of the 2-hydroxy-4-methylthiobutyric acid ammonium salt produced by this p...
|
|
WO/2004/089885A1 |
The invention relates to substituted phenoxyacetic acids (I) as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
|
|
WO/2004/089886A1 |
Pleuromutilin compounds of the formula (IA), (IB) are of use in antibacterial therapy.
|
|
WO/2004/087644A1 |
The present invention relates to the field of pharmaceuticals and organic chemistry and provides novel mercapto phenyl naphthyl methane derivatives, their pharmaceutically acceptable salts and compositions and preparation thereof, that a...
|
|
WO/2004/087064A2 |
The present invention relates to a novel method for the treatment of neoplasia, including cancer and other diseases and conditions in humans and mammals. More particularly, in preferred aspects, the present invention provides a method fo...
|
|
WO/2004/083867A2 |
The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In certain embodiments, the GPCR is human. In certain embodiments, the GPCR is expressed endogeno...
|
|
WO/2004/083258A2 |
The present invention provides branched water-soluble polymers that allow two or more water-soluble polymers to be conjugated to another species. The branched polymers provide access to therapeutic agents that are conjugated at a single ...
|
|
WO/2004/081073A2 |
Methods of selectively removing counterions from compounds are disclosed. Compounds derived from the methods, such as the compound S-[2-[(1Iminoethyl)amino]ethyl] -2-methyl-L-cysteine zwitterion with between zero and up to 2 molar equi...
|
|
WO/2004/080953A1 |
A crystalline salicylate monohydrate salt of S-[2-[(1-Iminoethyl)amino]ethyl]-2methyl-L-cysteine is disclosed. A method to make crystalline S-[2-[(1Iminoethyl)amino]ethyl]-2-methyl-L-cysteine is further disclosed. In addition, method...
|
|
WO/2004/080956A1 |
A novel mixed salt of S-[2-[(1-Iminoethyl)amino]ethyl] -2-methyl-L-cysteine is disclosed. The novel mixed salt, S-[2-[(1 Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride, may be produced to form crystals that may be arra...
|
|
WO/2004/080955A1 |
A crystalline maleate salt of S-[2-[(l -Iminoethyl)aminojethyl]-2-methyl-L-cysteine is disclosed. The crystalline salt has absorption of less than one percent water by weight at 90% R.H. at 25 °C, a melting point of 123 °C, and aqueous...
|
|
WO/2004/080954A1 |
Form II crystalline maleate salt of S-[2-[(1-Iminoethyl)amino]ethyl] -2-methyl-L-cysteine is disclosed. The Form II crystalline salt is a channel hydrate, with a melting point of about 77.69 °C.
|
|
WO/2004/078705A1 |
The invention relates to a method for producing &agr -(3-arylthio)-acetophenones of general formula (I), in which substituents R1 and R2, independent of one another, represent C1-C6 alkyl or an optionally substituted phenyl radical or be...
|
|
WO/2004/078765A2 |
The invention relates to bisphenolate ligand systems and related compounds, transition metal compounds containing said inventive ligand systems, a catalyst system for the polymerization of unsaturated compounds containing at least one in...
|
|
WO/2004/076475A1 |
The present invention relates to a method of generating polydentate metal chelating affinity ligands, which method comprises the steps of providing a cyclic scaffold comprising a carbonyl, an adjacent sulphur and a nucleophile; providing...
|
|
WO/2004/076404A1 |
Optically active compounds having thio groups at the 2-position which are important to the production of drugs and so on can be produced with minimized racemization in high yield and at a low cost by chlorinating an optically active comp...
|
|
WO/2004/075827A2 |
Process for the preparation of 2-[(diphenylmethyl)thioacetamide, an intermediate for the preparation of Modafinil which is a CNS stimulant and used for the treatment of narcolepsia. The process comprises reacting 2-[(diphenylmethyl)thio]...
|
|
WO/2004/075841A2 |
The present invention is directed to an improved process for preparing modafinil wherein benzhydrylthioacetamide is prepared in high yield and purity by the reaction of a haloacetamide with the reaction product of thiourea and benzhydrol...
|
|
WO/2004/074238A1 |
Compounds of formula (I): (I)are effective in the treatment of protein tyrosine phosphatase (PTPase) mediated disorders such as diabetes.
|
|
WO/2004/073606A2 |
The present invention is directed to a compound of Formula (I):, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferat...
|
|
WO/2004/074239A1 |
The invention relates to acylated aminopropanediols and the nitrogen and sulphur analogues thereof, having general formula (I), wherein R, R1, R2, R3, G2 and G3 are defined as in the claims. The invention also relates to pharmaceutical c...
|
